CRU Global is increasingly collaborating with investment firms, venture capital, and private equity companies to accelerate the early-phase development of emerging BioTech and MedTech companies.

Currently, our two primary investment partners are CR-Ventures (Boston) and PMK-Ventures (Singapore). In the near future, a European fund and a Singaporean fund will also join this clinical development accelerator program. Additionally, we are in active discussions with university funds and other stakeholders who are interested in our de-risking, accelerator model.